方盛制药
(603998)
| 流通市值：52.27亿 | | | 总市值：52.89亿 |
| 流通股本：4.34亿 | | | 总股本：4.40亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 438,354,992.77 | 1,628,542,252.04 | 1,214,912,885.84 | 855,215,463.45 |
| 营业收入 | 438,354,992.77 | 1,628,542,252.04 | 1,214,912,885.84 | 855,215,463.45 |
| 二、营业总成本 | 376,020,762.61 | 1,474,391,400.57 | 1,075,791,850.72 | 754,315,876.01 |
| 营业成本 | 117,538,344 | 519,538,143.5 | 375,024,291.9 | 263,490,852.83 |
| 税金及附加 | 7,631,835.09 | 29,269,534.75 | 21,854,607.73 | 14,781,265.94 |
| 销售费用 | 188,863,983.21 | 657,531,359.08 | 505,086,452.98 | 360,019,274.24 |
| 管理费用 | 32,700,390.01 | 149,308,230.41 | 109,123,128.19 | 75,046,116.84 |
| 研发费用 | 25,967,608.24 | 107,925,711.87 | 57,211,016.94 | 36,810,210.02 |
| 财务费用 | 3,318,602.06 | 10,818,420.96 | 7,492,352.98 | 4,168,156.14 |
| 其中:利息费用 | 6,286,765.12 | 20,807,928.59 | 14,793,983.59 | 8,944,229.14 |
| 其中:利息收入 | 4,813,095.25 | 10,642,310.78 | 7,500,930.47 | 5,287,614.15 |
| 加:公允价值变动收益 | - | 49,100.85 | 72,674.04 | 69,399.4 |
| 加:投资收益 | 2,462,137.7 | -3,851,216.35 | 5,024,294.87 | 7,132,551.3 |
| 资产处置收益 | 249,494.98 | 11,527,315.65 | -411,576.44 | -334,806.33 |
| 资产减值损失(新) | 317,468.79 | -2,334,432.93 | 290,927.48 | -58,669.62 |
| 信用减值损失(新) | -3,509,358.28 | -2,557,504.22 | 2,683,864 | 2,849,674.94 |
| 其他收益 | 17,150,831.33 | 39,461,496.71 | 12,553,865.94 | 11,467,849.45 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 79,004,804.68 | 196,445,611.18 | 159,335,085.01 | 122,025,586.58 |
| 加:营业外收入 | 111,075.1 | 8,553,241.6 | 370,868.49 | 322,390.9 |
| 减:营业外支出 | 125,267.91 | 1,660,555.67 | 1,191,278.46 | 1,040,289.14 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 78,990,611.87 | 203,338,297.11 | 158,514,675.04 | 121,307,688.34 |
| 减:所得税费用 | 10,725,709.66 | 23,714,394.65 | 17,895,463.49 | 15,239,261.42 |
| 六、净利润 | 68,264,902.22 | 179,623,902.46 | 140,619,211.55 | 106,068,426.92 |
| 持续经营净利润 | 68,264,902.22 | 179,623,902.46 | 140,619,211.55 | 106,068,426.92 |
| 归属于母公司股东的净利润 | 70,192,886.65 | 186,823,361.94 | 141,998,422.1 | 106,714,860.82 |
| 少数股东损益 | -1,927,984.44 | -7,199,459.48 | -1,379,210.55 | -646,433.9 |
| (一)基本每股收益 | 0.16 | 0.43 | 0.33 | 0.25 |
| (二)稀释每股收益 | 0.16 | 0.42 | 0.33 | 0.25 |
| 九、综合收益总额 | 68,264,902.22 | 179,623,902.46 | 140,619,211.55 | 106,068,426.92 |
| 归属于母公司股东的综合收益总额 | 70,192,886.65 | 186,823,361.94 | 141,998,422.1 | 106,714,860.82 |
| 归属于少数股东的综合收益总额 | -1,927,984.44 | -7,199,459.48 | -1,379,210.55 | -646,433.9 |
| 公告日期 | 2024-04-20 | 2024-04-20 | 2023-10-26 | 2023-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |